| 00:00:00 | Welcome |
| 00:00:11 | Introduction |
| 00:00:36 | Complex Generics: Orthogonal Characterization of Microemulsions |
| 00:00:58 | Agenda: |
| 00:01:18 | Untitled |
| 00:03:31 | Complex Generics |
| 00:04:12 | Untitled |
| 00:06:22 | Untitled |
| 00:07:23 | Microemulsions |
| 00:09:11 | Microemulsions: Ophthalmics |
| 00:10:49 | Ophthalmics: Characterization for Generics - Deformulation and IVBE |
| 00:12:32 | Particle size characterization of microemulsions |
| 00:14:54 | Microemulsions : Processing |
| 00:14:59 | Technique: Dynamic Light Scattering (DLS) |
| 00:16:15 | Microemulsions : Processing |
| 00:16:30 | Technique: Dynamic Light Scattering (DLS) |
| 00:16:40 | Untitled |
| 00:17:37 | Untitled |
| 00:18:45 | Untitled |
| 00:19:28 | Technique: Laser Diffraction (cont.) |
| 00:20:37 | Microemulsions for Ophthalmics: Cyclosporine globule size distribution |
| 00:21:14 | Measuring Zeta Potential |
| 00:21:52 | Measuring Zeta Potential |
| 00:23:05 | Measuring Electrophoretic Mobility – Zeta Potential |
| 00:24:50 | Ophthalmic microemulsions: Cyclosporine zeta potential |
| 00:25:41 | Rheology |
| 00:28:42 | Rheology of Microemulsions |
| 00:30:32 | Reason for Shear Rate Dependency |
| 00:31:47 | More ‘Rheology’ from increase in fluid structure |
| 00:34:08 | Ophthalmics: Cyclosporine viscosity vs. shear rate |
| 00:34:43 | Reason for Shear Rate Dependency |
| 00:35:02 | Ophthalmics: Cyclosporine viscosity vs. shear rate |
| 00:35:58 | Ophthalmics: Cyclosporine viscosity vs. shear rate |
| 00:36:34 | Dilution effects: |
| 00:37:31 | Ophthalmics: modified cellulose (HEC) |
| 00:38:21 | Ophthalmics: Cyclosporine viscoelasticity |
| 00:41:43 | Summary: Orthogonal Characterization- Microemulsions |
| 00:41:48 | Thank You for Your Time |
| 00:41:56 | Thank you for your attentionAny questions? |
| 00:45:58 | Contact Information |
Ophthalmic microemulsion drugs such as Restasis, indicated for dry eye syndrome, are speciality pharmaceuticals, and are considered complex generics because of their route of delivery and localized activity. Complex generics are challenging to produce, particularly so when it comes to proving bioequivalence with the corresponding Reference Listed Drug.
This webinar aims to provide a guide for proper physical characterization of microemulsions, specifically considering some of the issues with the complexity of such formulations.
This webinar aims to provide a guide for proper physical characterization of microemulsions, specifically considering some of the issues with the complexity of such formulations.
발표자
Anand Tadas holds a Masters degree in Physical Chemistry and a Doctorate in Colloidal Physics from the University of Mumbai. He has been awarded 4 US patents. Anand has worked for Malvern Aimil as a Technical Specialist for our nanometrics & rheology product ranges for the past 7 years.
자세한 내용
Who should attend?
Anyone working within the Pharmaceutical and Biopharmaceutical industries who has an interest in formulation/analytical development. Also, those who are interested in bioequivalence, deformulation, and the development of complex generic drugs.
Anyone working within the Pharmaceutical and Biopharmaceutical industries who has an interest in formulation/analytical development. Also, those who are interested in bioequivalence, deformulation, and the development of complex generic drugs.